GlassScriptPhysician profile
Whitney D Brooks
NPI 1558305128
$2,006.33
in general payments reported to CMS, 2019-2025
19 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $11.69 · 2022: $230 · 2023: $262 · 2024: $331 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250 · Education: $24.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.18 |
| Education | $24.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.03 | 2022-2025 | Viberzi, Linzess, Skyrizi |
| Boston Scientific Corporation | $286.68 | 2019-2022 | |
| Gilead Sciences, INC. | $185.76 | 2019-2025 | |
| Janssen Biotech, INC. | $132.21 | 2019-2023 | Stelara |
| Janssen Scientific Affairs, LLC | $124.20 | 2019 | |
| Medtronic, INC. | $68.06 | 2025 | Gi Genius |
| Fujifilm Healthcare Americas Corporation | $56.95 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.80 | 2022-2023 | Gattex |
| Ardelyx, INC. | $54.59 | 2025 | Ibsrela |
| Lilly USA, LLC | $48.88 | 2025 | Omvoh |
| Genzyme Corporation | $46.70 | 2023 | |
| Enterra Medical, INC. | $42.29 | 2025 | |
| Daiichi Sankyo INC. | $37.18 | 2019-2023 | Injectafer |
| Aimmune Therapeutics, INC. | $36.07 | 2024 | |
| Celltrion USA INC. | $24.39 | 2024 | Zymfentra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $22.27 | 2022-2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| W. L. Gore & Associates, INC. | $19.60 | 2023 | Gore Cardioform Septal Occluder |
| Madrigal Pharmaceuticals | $15.48 | 2024 | Resmetirom |
| Celgene Corporation | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.